Literature DB >> 33504059

Cancer of Unknown Primary: Challenges and Progress in Clinical Management.

Noemi Laprovitera1,2, Mattia Riefolo1, Elisa Ambrosini1, Christiane Klec3, Martin Pichler3, Manuela Ferracin1.   

Abstract

Distant metastases are the main cause of cancer-related deaths in patients with advanced tumors. A standard diagnostic workup usually contains the identification of the tissue-of-origin of metastatic tumors, although under certain circumstances, it remains elusive. This disease setting is defined as cancer of unknown primary (CUP). Accounting for approximately 3-5% of all cancer diagnoses, CUPs are characterized by an aggressive clinical behavior and represent a real therapeutic challenge. The lack of determination of a tissue of origin precludes CUP patients from specific evidence-based therapeutic options or access to clinical trial, which significantly impacts their life expectancy. In the era of precision medicine, it is essential to characterize CUP molecular features, including the expression profile of non-coding RNAs, to improve our understanding of CUP biology and identify novel therapeutic strategies. This review article sheds light on this enigmatic disease by summarizing the current knowledge on CUPs focusing on recent discoveries and emerging diagnostic strategies.

Entities:  

Keywords:  cancers of unknown primary site; clinical management; liquid biopsy; molecular profiling; primary site identification

Year:  2021        PMID: 33504059      PMCID: PMC7866161          DOI: 10.3390/cancers13030451

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  202 in total

1.  Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Authors:  Cécile Jovelet; Ecaterina Ileana; Marie-Cécile Le Deley; Nelly Motté; Silvia Rosellini; Alfredo Romero; Celine Lefebvre; Marion Pedrero; Noémie Pata-Merci; Nathalie Droin; Marc Deloger; Christophe Massard; Antoine Hollebecque; Charles Ferté; Amélie Boichard; Sophie Postel-Vinay; Maud Ngo-Camus; Thierry De Baere; Philippe Vielh; Jean-Yves Scoazec; Gilles Vassal; Alexander Eggermont; Fabrice André; Jean-Charles Soria; Ludovic Lacroix
Journal:  Clin Cancer Res       Date:  2016-01-12       Impact factor: 12.531

2.  Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites.

Authors:  O Kaufmann; M Dietel
Journal:  Histopathology       Date:  2000-05       Impact factor: 5.087

Review 3.  Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients.

Authors:  T Le Chevalier; E Cvitkovic; P Caille; J Harvey; G Contesso; M Spielmann; J Rouesse
Journal:  Arch Intern Med       Date:  1988-09

4.  Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary.

Authors:  Roger Olofsson Bagge; Akif Demir; Joakim Karlsson; Babak Alaei-Mahabadi; Berglind O Einarsdottir; Henrik Jespersen; Mattias F Lindberg; Andreas Muth; Lisa M Nilsson; Marta Persson; Johanna B Svensson; Elin M V Söderberg; Ronald R de Krijger; Ola Nilsson; Erik Larsson; Göran Stenman; Jonas A Nilsson
Journal:  JCO Precis Oncol       Date:  2018-07-30

5.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

6.  Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.

Authors:  Justin A Bishop; Rajni Sharma; Peter B Illei
Journal:  Hum Pathol       Date:  2009-09-08       Impact factor: 3.466

7.  Donor-derived breast cancer in a bone marrow transplantation recipient.

Authors:  Vassilis Golfinopoulos; Vassilis Golfinopouloss; George Pentheroudakis; Smaragda Kamakari; Vasiliki Metaxa-Mariatou; Nicholas Pavlidis
Journal:  Breast Cancer Res Treat       Date:  2008-02-09       Impact factor: 4.872

8.  Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.

Authors:  Koushan Siami; W Glenn McCluggage; Nelson G Ordonez; Elizabeth D Euscher; Anais Malpica; Nour Sneige; Elvio G Silva; Michael T Deavers
Journal:  Am J Surg Pathol       Date:  2007-11       Impact factor: 6.394

9.  Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.

Authors:  Alexander Penson; Niedzica Camacho; Youyun Zheng; Anna M Varghese; Hikmat Al-Ahmadie; Pedram Razavi; Sarat Chandarlapaty; Christina E Vallejo; Efsevia Vakiani; Teresa Gilewski; Jonathan E Rosenberg; Maha Shady; Dana W Y Tsui; Dalicia N Reales; Adam Abeshouse; Aijazuddin Syed; Ahmet Zehir; Nikolaus Schultz; Marc Ladanyi; David B Solit; David S Klimstra; David M Hyman; Barry S Taylor; Michael F Berger
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

Review 10.  How I treat cancers of unknown primary.

Authors:  George Zarkavelis; Davide Mauri; George Pentheroudakis
Journal:  ESMO Open       Date:  2019-05-10
View more
  2 in total

1.  Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches.

Authors:  Noemi Laprovitera; Irene Salamon; Francesco Gelsomino; Elisa Porcellini; Mattia Riefolo; Marianna Garonzi; Paola Tononi; Sabrina Valente; Silvia Sabbioni; Francesca Fontana; Nicolò Manaresi; Antonia D'Errico; Maria A Pantaleo; Andrea Ardizzoni; Manuela Ferracin
Journal:  Front Cell Dev Biol       Date:  2021-06-10

2.  MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.

Authors:  Noemi Laprovitera; Mattia Riefolo; Elisa Porcellini; Giorgio Durante; Ingrid Garajova; Francesco Vasuri; Ariane Aigelsreiter; Nadia Dandachi; Giuseppe Benvenuto; Federico Agostinis; Silvia Sabbioni; Ioana Berindan Neagoe; Chiara Romualdi; Andrea Ardizzoni; Davide Trerè; Martin Pichler; Antonietta D'Errico; Manuela Ferracin
Journal:  Mol Oncol       Date:  2021-06-23       Impact factor: 6.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.